Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NYVAC HIV-C
- Development stage
- Phase 2
- Lead developer
- EuroVacc Foundation
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
NYVAC HIV-C (also known as NYVAC-C or vP2010) is an investigational recombinant poxvirus-based vaccine candidate designed for the prevention of HIV-1 infection, specifically targeting subtype C (clade C). Developed by the EuroVacc Foundation and manufactured by Sanofi Pasteur, the vaccine utilizes the highly attenuated New York vaccinia (NYVAC) poxvirus backbone. It is engineered to express multiple HIV-1 clade C antigens, including Gag, Pol, Env (gp120), and Nef, derived from the Chinese clade C isolate CN54. The vaccine aims to elicit both cell-mediated (T cell) and humoral immune responses. It has been evaluated in Phase I clinical trials (such as EV01 and EV02) both as a standalone agent and as part of a heterologous prime-boost regimen following a DNA-based HIV-C vaccine.
- Other names
- NYVAC-CvP2010vP-2010vP 2010
02
Targets
Gag (HIV-1 Gag polyprotein)Nef (HIV-1 Nef)gp41 (Human immunodeficiency virus type 1 glycoprotein 41)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on NYVAC HIV-C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NYVAC HIV-C.